These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36781850)

  • 61. Combination of chemotherapy and all-trans retinoic acid for the treatment KMT2A-rearranged infant acute lymphoblastic leukemia. Results of the MLL-Baby trial.
    Fechina L; Popov A; Tsaur G; Henze G; Shorikov E; Makarova O; Khlebnikova O; Zhukova Y; Arakaev O; Streneva O; Verzhbitskaya T; Riger T; Solodovnikov A; Lapotentova E; Aleinikova O; Myakova N; Boichenko E; Kondratchik K; Nikonova O; Shapochnik A; Goroshkova M; Ponomareva N; Novichkova G; Karachunskiy A; Roumiantsev A
    Leukemia; 2023 Nov; 37(11):2276-2281. PubMed ID: 37741948
    [No Abstract]   [Full Text] [Related]  

  • 62. Chromatin and aberrant enhancer activity in KMT2A rearranged acute lymphoblastic leukemia.
    Milne TA
    Curr Opin Genet Dev; 2024 Jun; 86():102191. PubMed ID: 38579381
    [TBL] [Abstract][Full Text] [Related]  

  • 63. High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR-ABL1-like acute lymphoblastic leukemia.
    Lee JW; Kim Y; Cho B; Kim S; Jang PS; Lee J; Cho H; Lee GD; Chung NG; Kim M
    Cancer Med; 2020 Jul; 9(13):4632-4639. PubMed ID: 32378810
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The EGR3 regulome of infant KMT2A-r acute lymphoblastic leukemia identifies differential expression of B-lineage genes predictive for outcome.
    Külp M; Larghero P; Alten J; Cario G; Eckert C; Caye-Eude A; Cavé H; Schmachtel T; Bardini M; Cazzaniga G; De Lorenzo P; Valsecchi MG; Bonig H; Meyer C; Rieger MA; Marschalek R
    Leukemia; 2023 Jun; 37(6):1216-1233. PubMed ID: 37100882
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols.
    Motlló C; Ribera JM; Morgades M; Granada I; Montesinos P; Brunet S; Bergua J; Tormo M; García-Boyero R; Sarrà J; Del Potro E; Grande C; Barba P; Bernal T; Amigo ML; Grau J; Cervera J; Feliu E;
    Leuk Lymphoma; 2017 Jan; 58(1):145-152. PubMed ID: 27122129
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A novel regimen for relapsed/refractory adult acute myeloid leukemia using a
    Mims AS; Mishra A; Orwick S; Blachly J; Klisovic RB; Garzon R; Walker AR; Devine SM; Walsh KJ; Vasu S; Whitman S; Marcucci G; Jones D; Heerema NA; Lozanski G; Caligiuri MA; Bloomfield CD; Byrd JC; Piekarz R; Grever MR; Blum W
    Haematologica; 2018 Jun; 103(6):982-987. PubMed ID: 29567781
    [No Abstract]   [Full Text] [Related]  

  • 67. MLL gene in maternal and infantile acute lymphoblastic leukemia and the effect of estrogen.
    Aljurf M; Saleh AJ; Ahmed SO
    Leuk Res; 2011 Jul; 35(7):e127. PubMed ID: 21396712
    [No Abstract]   [Full Text] [Related]  

  • 68. Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation.
    Nguyen D; Kantarjian HM; Short NJ; Qiao W; Ning J; Cuglievan B; Daver NG; DiNardo CD; Jabbour EJ; Kadia TM; Borthakur G; Garcia-Manero G; Konopleva MY; Andreeff M; Ravandi-Kashani F; Sasaki K; Issa GC
    Cancer; 2023 Jun; 129(12):1856-1865. PubMed ID: 36892949
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Lineage switch from acute myeloid leukemia with KMT2A-PTD to mixed phenotype acute leukemia with t(v;11q23).
    Li T; Chen M; Fu M; Wang A; Wang H
    Int J Lab Hematol; 2022 Feb; 44(1):21-22. PubMed ID: 34643033
    [No Abstract]   [Full Text] [Related]  

  • 70. Osteopontin-c is overexpressed in KMT2A-AFF1 positive pediatric B-cell lymphoblastic leukemia when compared to those with ETV6-RUNX1".
    da Fonseca Bastos ACS; da Silva Rezende AC; Ferreira LB; Blunck CB; Pombo-de-Oliveira MS; Emerenciano M; Gimba ERP
    Leuk Res; 2020 Apr; 91():106316. PubMed ID: 32114371
    [No Abstract]   [Full Text] [Related]  

  • 71. Genetic characteristics and treatment outcome in infants with KMT2A germline B-cell precursor acute lymphoblastic leukemia: Results of MLL-Baby protocol.
    Popov A; Tsaur G; Permikin Z; Henze G; Verzhbitskaya T; Plekhanova O; Nokhrina E; Valochnik A; Sibiryakov P; Zerkalenkova E; Olshanskaya Y; Gindina T; Movchan L; Shorikov E; Streneva O; Khlebnikova O; Makarova O; Arakaev O; Boichenko E; Kondratchik K; Ponomareva N; Lapotentova E; Aleinikova O; Miakova N; Novichkova G; Karachunskiy A; Fechina L
    Pediatr Blood Cancer; 2023 Apr; 70(4):e30204. PubMed ID: 36715125
    [TBL] [Abstract][Full Text] [Related]  

  • 72. MLL/KMT2A translocations in diffuse large B-cell lymphomas.
    Gindin T; Murty V; Alobeid B; Bhagat G
    Hematol Oncol; 2015 Dec; 33(4):239-46. PubMed ID: 25131304
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A novel KMT2A-ACTN2 fusion in infant B-cell acute lymphoblastic leukemia.
    Yoshida M; Nakabayashi K; Ogata-Kawata H; Osumi T; Tsujimoto SI; Shirai R; Yoshida K; Okamura K; Matsumoto K; Kiyokawa N; Tomizawa D; Hata K; Kato M
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27821. PubMed ID: 31115144
    [No Abstract]   [Full Text] [Related]  

  • 74. Towards targeted therapy for infant acute lymphoblastic leukaemia.
    Stam RW; den Boer ML; Pieters R
    Br J Haematol; 2006 Mar; 132(5):539-51. PubMed ID: 16445826
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Identification of KMT2A-ARHGEF12 fusion in a child with a high-grade B-cell lymphoma.
    Schafernak KT; Williams JA; Clyde BI; Marcus C; Decker B; Toydemir RM
    Cancer Genet; 2021 Nov; 258-259():23-26. PubMed ID: 34237703
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinicopathologic and prognostic features of TdT-negative pediatric B-lymphoblastic leukemia.
    Klairmont MM; Zhou Y; Cheng C; Pui CH; Jeha S; Gruber TA; Liu Y; Inaba H; Choi JK
    Mod Pathol; 2021 Nov; 34(11):2050-2054. PubMed ID: 34148065
    [TBL] [Abstract][Full Text] [Related]  

  • 77. HMGA2 as a potential molecular target in KMT2A-AFF1-positive infant acute lymphoblastic leukaemia.
    Wu Z; Eguchi-Ishimae M; Yagi C; Iwabuki H; Gao W; Tauchi H; Inukai T; Sugita K; Ishii E; Eguchi M
    Br J Haematol; 2015 Dec; 171(5):818-29. PubMed ID: 26403224
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.
    Stam RW; Den Boer ML; Schneider P; de Boer J; Hagelstein J; Valsecchi MG; de Lorenzo P; Sallan SE; Brady HJ; Armstrong SA; Pieters R
    Blood; 2010 Feb; 115(5):1018-25. PubMed ID: 19965632
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Outcome of recurrent or refractory acute lymphoblastic leukemia in infants with MLL gene rearrangements: A report from the Japan Infant Leukemia Study Group.
    Tomizawa D; Koh K; Hirayama M; Miyamura T; Hatanaka M; Saikawa Y; Ishii E
    Pediatr Blood Cancer; 2009 Jul; 52(7):808-13. PubMed ID: 19229974
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric
    Pollard JA; Guest E; Alonzo TA; Gerbing RB; Loken MR; Brodersen LE; Kolb EA; Aplenc R; Meshinchi S; Raimondi SC; Hirsch B; Gamis AS
    J Clin Oncol; 2021 Oct; 39(28):3149-3160. PubMed ID: 34048275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.